Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Senti Biosciences (SNTI) Accumulated Depreciation & Amortization (2021 - 2025)

Senti Biosciences has reported Accumulated Depreciation & Amortization over the past 5 years, most recently at $13.1 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 36.71% year-over-year to $13.1 million; the TTM value through Dec 2025 reached $13.1 million, up 36.71%, while the annual FY2025 figure was $13.1 million, 36.71% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $13.1 million at Senti Biosciences, up from $12.2 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $13.1 million in Q4 2025 and troughed at $1.7 million in Q4 2021.
  • A 5-year average of $6.8 million and a median of $6.6 million in 2023 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: surged 109.2% in 2023 and later surged 36.71% in 2025.
  • Year by year, Accumulated Depreciation & Amortization stood at $1.7 million in 2021, then soared by 78.55% to $3.0 million in 2022, then surged by 109.2% to $6.2 million in 2023, then surged by 54.5% to $9.6 million in 2024, then skyrocketed by 36.71% to $13.1 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for SNTI at $13.1 million in Q4 2025, $12.2 million in Q3 2025, and $11.3 million in Q2 2025.